Strumento inattivo

Altre lingue Tekmira Pharmaceuticals Corporation Toronto S.E.

Azioni

TKM

CA87911B2093

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Treatment with Arbutus Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels	07/06
Arbutus Biopharma Says Imdusiran Plus VTP-300 Therapy Lowers HBsAg Levels in Trial	06/06
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels	06/06
Arbutus Biopharma Corporation Announces New Preliminary End-Of- Treatment Data from the Phase 2A Clinical Trial	06/06
Arbutus Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure	06/06
Arbutus Biopharma : Corporate Presentation - June 2024	05/06
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure	05/06
Arbutus Biopharma Corporation Announces New Data from its Phase 2a Clinical Trial IM-PROVE I (AB-729-201)	05/06
Arbutus to Participate in Jefferies Global Healthcare Conference	29/05
Arbutus to Present Imdusiran Data at EASL Congress 2024	22/05
Arbutus to Present Imdusiran Data at EASL Congress 2024	22/05
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value	20/05
Whitefort Capital Management Sends an Open Letter to Shareholders of Arbutus Biopharma	20/05
Sector Update: Health Care Stocks Mixed Late Afternoon	17/05
Sector Update: Health Care Stocks Softer Friday Afternoon	17/05
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program	17/05
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program	17/05
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value	17/05
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders	17/05
Investor Whitefort urges Arbutus Biopharma to halt stock sales, find partner	17/05

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Tekmira Pharmaceuticals Corporation Toronto S.E.

Azioni

TKM

CA87911B2093

Altre lingue

Filtri